An interventional study of Health Education Program and SMART3RP-Lymphoma in Lymphoma, sponsored by Massachusetts General Hospital. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Supportive care
The goal of this trial is to learn if a resilience intervention can lead to improvements in lymphoma survivors' quality of life.
The Stress Management and Relaxation Response Resiliency Program for lymphoma survivors (SMART3RP-Lymphoma) was adapted by researchers at the MGH. This group program seeks to buffer stress and promote psychological resiliency and physical well-being through a variety of mind-body approaches, such as imagery, relaxation, and yoga, cognitive behavioral strategies, and positive psychology tools.
The main questions it aims to answer are:
To answer these questions, researchers will compare a resilience intervention tailored to the needs of lymphoma survivors (SMART3RP-Lymphoma) to a Health Education Program to see how they affect quality of life of lymphoma survivors.
Participants will:
Exclusion Criteria:
Participants will participate in 8 weekly sessions. Components include: * education on the co-occurrence of mental and physical problems * goal setting for health behavior change * self-monitoring HEP is an active control condition for mind body programs and is structurally equivalent to SMART3RP
Other: Health Education Program
Participants will participate in 8 weekly sessions. The intervention components include: * Eliciting the relaxation response (RR), * CBT strategies to improve stress management * Positive psychology strategies to achieve growth enhancement
Other: SMART3RP-Lymphoma
8 weekly sessions that include education on the co-occurrence of mental and physical problems, goal setting for health behavior change, and self-monitoring. Each session includes basic didactic information, interactive application of the information, and open discussion of didactic material.
The SMART3RP-lymphoma is a group program that, through a variety of mind-body approaches, such as imagery, relaxation, and yoga, seeks to buffer stress and promote psychological resiliency and physical well-being.
Quality of Life (QoL): Change in PROMIS-29
To examine the effects of the SMART3RP-Lymphoma vs. a Health Education Program (HEP) in improving quality of life in early posttreatment lymphoma survivors. Quality of life will be measured using the PROMIS-29 which assesses physical, functional, emotional, and social quality of life. Each survey item is measured on a 1-5 scale. The unit of measurement is a score on a scale.
Time frame: From enrollment to 6 month follow up
Resilience: Change in Scores on the Current Experiences Scale (CES)
To compare the effects of the SMART3RP-Lymphoma vs. a Health Education Program (HEP) on resilience in posttreatment lymphoma survivors. Resilience will be measured by the Current Experiences Scale (CES). The CES is a 23-item measure that assesses the following domains of resilience on 0-5 scale: appreciation for life, adaptive perspectives, personal strength, spiritual connectedness, relating to others, and health behaviors. The unit of measurement is a score on a scale.
Time frame: Enrollment to 3 month follow up
Correlation between scores on measures of Resilience (CES) and Quality of Life (PROMIS-29)
The investigators will determine how resilience at 3 months correlates to quality-of-life improvements at 6 and 12 months. Resilience will be measured by the Current Experiences Scale (CES), which is a 23-item measure. The CES assesses 6 domains of resilience including appreciation for life, adaptive perspectives, personal strength, spiritual connectedness, relating to others, and health behaviors). Quality of life will be measured by the PROMIS-29 which is a 29-item measure. It assesses physical, functional, emotional, and social quality of life domains. The unit of measurement for both assessments are scores on a scale.
Time frame: 3, 6 and 12 months
Plan to share: Yes — de-identified information as required by the NIH
Supporting information: Study protocol, Sap
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital